JP2017513902A5 - - Google Patents

Download PDF

Info

Publication number
JP2017513902A5
JP2017513902A5 JP2016564162A JP2016564162A JP2017513902A5 JP 2017513902 A5 JP2017513902 A5 JP 2017513902A5 JP 2016564162 A JP2016564162 A JP 2016564162A JP 2016564162 A JP2016564162 A JP 2016564162A JP 2017513902 A5 JP2017513902 A5 JP 2017513902A5
Authority
JP
Japan
Prior art keywords
fcrn
afp
pharmaceutical composition
composition according
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016564162A
Other languages
English (en)
Japanese (ja)
Other versions
JP6792454B2 (ja
JP2017513902A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/026860 external-priority patent/WO2015164364A2/en
Publication of JP2017513902A publication Critical patent/JP2017513902A/ja
Publication of JP2017513902A5 publication Critical patent/JP2017513902A5/ja
Application granted granted Critical
Publication of JP6792454B2 publication Critical patent/JP6792454B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016564162A 2014-04-25 2015-04-21 アルファ−フェトプロテイン(afp)を操作するための方法 Active JP6792454B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461984252P 2014-04-25 2014-04-25
US61/984,252 2014-04-25
US201562101539P 2015-01-09 2015-01-09
US62/101,539 2015-01-09
PCT/US2015/026860 WO2015164364A2 (en) 2014-04-25 2015-04-21 Methods to manipulate alpha-fetoprotein (afp)

Publications (3)

Publication Number Publication Date
JP2017513902A JP2017513902A (ja) 2017-06-01
JP2017513902A5 true JP2017513902A5 (OSRAM) 2018-06-07
JP6792454B2 JP6792454B2 (ja) 2020-11-25

Family

ID=54333408

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016564162A Active JP6792454B2 (ja) 2014-04-25 2015-04-21 アルファ−フェトプロテイン(afp)を操作するための方法

Country Status (6)

Country Link
US (4) US20170044257A1 (OSRAM)
EP (2) EP3804745A1 (OSRAM)
JP (1) JP6792454B2 (OSRAM)
AU (1) AU2015249946A1 (OSRAM)
CA (1) CA2983794A1 (OSRAM)
WO (1) WO2015164364A2 (OSRAM)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201520575D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
CN107561284B (zh) * 2016-03-25 2019-01-29 江苏迈源生物科技有限公司 易于操作的甲胎蛋白试剂盒
KR20190015704A (ko) 2016-04-25 2019-02-14 신티뮨, 인크. 인간화된 친화성 성숙 항-fcrn 항체
WO2018053069A1 (en) * 2016-09-16 2018-03-22 The Brigham And Women's Hospital, Inc. Blockade of alphafetoprotein (afp) interactions with beta2-microglobulin associated molecules
CN106916222B (zh) * 2017-04-18 2020-05-05 河北渤腾医药技术有限公司 甲胎蛋白检测试剂盒
JP7631187B2 (ja) * 2018-08-17 2025-02-18 ジェネンテック, インコーポレイテッド In vitroトランスサイトーシスアッセイ
WO2023198806A1 (en) * 2022-04-13 2023-10-19 Ose Immunotherapeutics New class of molecules for selective clearance of antibody

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3270960A (en) 1964-09-11 1966-09-06 Sperry Rand Corp Fluid sensor
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4747825A (en) 1984-06-29 1988-05-31 Ferring Laboratories, Inc. Apparatus and methodology for pulsed administration of growth promoting agents
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4948592A (en) 1986-05-09 1990-08-14 Alza Corporation Pulsed drug delivery
US4723958A (en) 1986-05-23 1988-02-09 Merck & Co., Inc. Pulsatile drug delivery system
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4965251A (en) 1987-04-03 1990-10-23 The Board Of Regents Of The University Of Washington Pulse treatment of hemoglobinopathies with erythropoietin
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
ATE408012T1 (de) 1991-12-02 2008-09-15 Medical Res Council Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
ATE182651T1 (de) 1992-06-09 1999-08-15 Hoppe Ag Riegel und türschloss
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5403590A (en) 1992-12-21 1995-04-04 New England Deaconess Hospital Corporation Method of pulsatile drug infusion
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
US20020110556A1 (en) * 1997-08-15 2002-08-15 Moro Ricardo J. Detection and treatment of cancer
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク. 免疫したゼノマウス(XenoMouse)に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
JPH11511847A (ja) * 1995-09-18 1999-10-12 ジェイ. モロ,リカード 癌の検出及び処理
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6365185B1 (en) 1998-03-26 2002-04-02 University Of Cincinnati Self-destructing, controlled release peroral drug delivery system
WO2006118772A2 (en) * 2005-04-29 2006-11-09 The Jackson Laboratory Fcrn antibodies and uses thereof
WO2010138814A2 (en) * 2009-05-29 2010-12-02 The Brigham And Women's Hospital, Inc. Disrupting fcrn-albumin interactions

Similar Documents

Publication Publication Date Title
JP2017513902A5 (OSRAM)
JP2014240385A5 (OSRAM)
RU2015154275A (ru) Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
JP2015534580A5 (OSRAM)
JP2018070648A5 (OSRAM)
RU2017115773A (ru) 17альфа-бензоат кортексолона для применения в лечении опухолей
AU2015219495B2 (en) Disease therapy by inducing immune response to Trop-2 expressing cells
JP2016502504A5 (OSRAM)
JP2012046518A5 (OSRAM)
JP2015500225A5 (OSRAM)
CO2017002233A2 (es) Compuestos de aminopiridiloxipirazol
JOP20210044A1 (ar) الأجسام المضادة لـ cd38
UA118255C2 (uk) Композиція, яка містить антитіло до cd38 і леналідомід
NZ630363A (en) Anti-kit antibodies and uses thereof
JP2015534577A5 (OSRAM)
IL276515B1 (en) PD–L1-specific antibodies and methods of using them
BR112017006468A2 (pt) anticorpo biespecífico, composição farmacêutica, kit, uso de uma combinação de um anticorpo biespecífico e método de tratamento de câncer
AU2017291414B2 (en) Anti-N3pGLu amyloid beta peptide antibodies and uses thereof
JP2008154589A5 (OSRAM)
JP2017527582A5 (OSRAM)
JP2017501848A5 (OSRAM)
JP2018515137A5 (OSRAM)
JP2015512412A5 (OSRAM)
IL282827A (en) Bispecific cd123 x cd3 diabodies for the treatment of hematologic malignancies